Diligence memo · auto-generated · as of July 2, 2026
Gut-Brain-Axis Therapeutics Inc.
Gut-Brain-Axis Therapeutics Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Gut-Brain-Axis Therapeutics Inc. operates in Biotechnology, based in TEMPE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gut-Brain-Axis Therapeutics Inc. has raised $3.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2025-10-31.
Most recent recorded round closed around 2025-10-31.
Valuation (modeled)modeled
Provath models Gut-Brain-Axis Therapeutics Inc. at approximately $4.6M (range $1.4M–$8.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 8 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 36% of Biotechnology peers (4293 compared).
Modeled value ranks above 10% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.